



Home Clinical trials Seroquel™ (quetiapine)

AstraZeneca websites

Search

Go

Advanced search

Corporate Responsibility

Bioethics Policy
Code of Conduct

Quick links - Products

- [Accolate™ \(zafirlukast\)](#)
- [Arimidex™ \(anastrozole\)](#)
- [Atacand™ \(candesartan cilexetil\)](#)
- [Casodex™ \(bicalutamide\)](#)
- [Crestor™ \(rosuvastatin\)](#)
- [Diprivan™ \(propofol\)](#)
- [Entocort™ \(budesonide\)](#)
- [Exanta™ \(ximelagatran\)](#)
- [Faslodex™ \(fulvestrant\)](#)
- [Iressa™ \(gefitinib\)](#)
- [Losec™ \(omeprazole\)](#)
- [Merrem™ \(meropenem\)](#)
- [Naropin™ \(ropivacaine\)](#)
- [Nexium™ \(esomeprazole\)](#)
- [Oxis™ \(formoterol\)](#)
- [Plendil™ \(felodipine\)](#)
- [Pulmicort™ \(budesonide\)](#)
- [Rhinocort™ \(budesonide\)](#)
- [Seloken ZOK/Toprol-XL™ \(metoprolol CR/XL\)](#)
- [Seroquel™ \(quetiapine\)](#)
- [- Ongoing Studies](#)
- [Symbicort™ \(budesonide/formoterol\)](#)
- [Tomudex™ \(raltitrexed\)](#)
- [Zoladex™ \(goserelin acetate\)](#)
- [Zomig™ \(zolmitriptan\)](#)
- [Products in Development](#)
- [Pulmicort™ \(budesonide\)](#)
- [Rhinocort™ \(budesonide\)](#)
- [Seloken ZOK/Toprol-XL™ \(metoprolol CR/XL\)](#)
- [Seroquel™ \(quetiapine\)](#)
- [Symbicort™ \(budesonide/formoterol\)](#)
- [Tomudex™ \(raltitrexed\)](#)
- [Zoladex™ \(goserelin acetate\)](#)
- [Zomig™ \(zolmitriptan\)](#)

Page tools

- [Bookmark this site](#)
- [Bookmark this page](#)
- [Printer friendly](#)
- [Print this chapter](#)

Home

Clinical trials

- [Accolate™ \(zafirlukast\)](#)
- [Arimidex™ \(anastrozole\)](#)
- [Atacand™ \(candesartan cilexetil\)](#)
- [Casodex™ \(bicalutamide\)](#)
- [Crestor™ \(rosuvastatin\)](#)
- [Diprivan™ \(propofol\)](#)
- [Entocort™ \(budesonide\)](#)
- [Exanta™ \(ximelagatran\)](#)
- [Faslodex™ \(fulvestrant\)](#)
- [Iressa™ \(gefitinib\)](#)
- [Losec™ \(omeprazole\)](#)
- [Merrem™ \(meropenem\)](#)
- [Naropin™ \(ropivacaine\)](#)
- [Nexium™ \(esomeprazole\)](#)
- [Oxis™ \(formoterol\)](#)
- [Plendil™ \(felodipine\)](#)
- [Pulmicort™ \(budesonide\)](#)
- [Rhinocort™ \(budesonide\)](#)
- [Seloken ZOK/Toprol-XL™ \(metoprolol CR/XL\)](#)
- [Seroquel™ \(quetiapine\)](#)
- [- Ongoing Studies](#)
- [Symbicort™ \(budesonide/formoterol\)](#)
- [Tomudex™ \(raltitrexed\)](#)
- [Zoladex™ \(goserelin acetate\)](#)
- [Zomig™ \(zolmitriptan\)](#)
- [Products in Development](#)
- [Non-Drug Trials](#)

Glossary

Contact us

Sitemap

Seroquel™ (quetiapine) Clinical Trial report summaries

Seroquel™ (quetiapine) was first approved in 1997 for schizophrenia. Since the formation of AstraZeneca, Seroquel™ (quetiapine) has received approval for bipolar mania.

Please consult the prescribing information for the country concerned for guidance on the approved use of Seroquel™ (quetiapine).

Study Number	Completed Clinical Trial Report Summaries
5077IL_0039	A Multicenter, Double-blind Comparison of Efficacy and Safety of Seroquel™ (Quetiapine Fumarate), Haloperidol, and Placebo in the Treatment of Elderly Subjects Residing in Nursing Homes or Assisted Care Facilities and Presenting with Alzheimer's Dementia and Psychoses or Other Selected Psychoses
5077IL_0050	A Multicentre, Double-blind, Randomised Trial to Compare the Effects of Quetiapine and Haloperidol Treatment Strategies on Treatment Outcomes (5077IL/0050[ESTO])
5077IL_0099	A Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the Safety and Efficacy of Seroquel™ (Quetiapine Fumarate) as Add-on Therapy with Lithium or Divalproex in the Treatment of Acute Mania
5077IL_0100	An International, Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Seroquel™ (Quetiapine Fumarate) as Add-on Therapy with Lithium or Divalproex in the Treatment of Acute Mania
5077IL_0104	An International, Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Seroquel™ (Quetiapine Fumarate) and Haloperidol as Monotherapy in the Treatment of Acute Mania
5077IL_0105	An International, Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Seroquel™ (Quetiapine Fumarate) and Lithium as Monotherapy in the Treatment of Acute Mania
5077US_0043	A Multicenter, Double-blind, Randomized Comparison of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™) and Risperidone (RISPERDAL™) in the Treatment of Patients with Schizophrenia
5077US_0046	A Multicenter, Double-blind, Randomized Comparison of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™) and Placebo in the Treatment of Agitation Associated with Dementia
5077US_0049	A Multicenter, Double-blind, Randomized, Placebo-controlled, Double-dummy Trial of the Use of Quetiapine Fumarate (Seroquel™) in the Treatment of Patients with Bipolar Depression
D1447C00135	A Confirmatory Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Use of Quetiapine Fumarate (Seroquel™) in the Treatment of Patients with Bipolar Depression.
D1444C00132	A 6-week, International, Multicenter, Double-blind, Double-dummy, Randomized Comparison of the Efficacy and Safety of Sustained-Release Formulation Quetiapine Fumarate (SEROQUEL™) and Placebo in the Treatment of Acutely Ill Patients with Schizophrenia.
D1444C00133	A 6-week, Multicenter, Double-blind, Double-dummy, Randomized Comparison of the Efficacy and Safety of Sustained-Release Formulation Quetiapine Fumarate



	(SEROQUEL™) and Placebo in the Treatment of Acutely Ill Patients with Schizophrenia.
5077IL_0041	A Multicenter, Double-blind, Randomized Comparison of the Efficacy and Safety of Sustained-release Formulation Quetiapine Fumarate (SEROQUEL™) and Placebo in the Treatment of Patients With Schizophrenia.
D1441C00023	A Canadian, Multicentre, Double-Blind, Randomized, Parallel-Group Study of the Safety, Tolerability, and Efficacy of Treatment with Higher Doses of Quetiapine Fumarate (Seroquel™) greater than 800 mg/day in Schizophrenic or Schizoaffective Subjects.
D1441C00125 (5077IL/125)	A Canadian, Multicentre, Double-Blind, Randomized, Parallel-Group Study of the Safety, Tolerability, and Efficacy of Treatment with Higher Doses of Quetiapine Fumarate (Seroquel™) greater than 800 mg/day in Schizophrenic or Schizoaffective Subjects.
1441C09907	Westenberg OCD study.
D1441L00002	Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomized Double Blind 52 Week Comparison.
BU-5077-0011 (D1441L00028)	Trial results awaiting further analysis and interpretation. Anticipated posting date is October 2008.
D1446L00002	A Multicenter, Double-blind, Randomized Comparison of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) and Placebo in the Treatment of Agitation Associated with Dementia
D1444C00004 (PRINCESS)	A 1-year, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Phase III Study to Evaluate Prevention of Relapse in Patients in Stable Condition with Chronic Schizophrenia Receiving Either Sustained-release Quetiapine Fumarate (SEROQUEL) or Placebo.
D1444C00146	A 6-week International, Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study to Evaluate the Feasibility of Switching from Immediate-release Quetiapine Fumarate (SEROQUEL™) to Sustained-release Quetiapine Fumarate (400 to 800 mg/day) in Outpatients with Schizophrenia .
D1444C00147	A 12-week International, Multicenter, Open Label, Non-comparative Study to Evaluate the Feasibility of Switching any Antipsychotic Treatment to Sustained-release quetiapine Fumarate (SEROQUEL®) in Patients with Schizophrenia
D1447C00126	Trial results awaiting further analysis and interpretation. Anticipated posting date is June 2008. Comparison.
D1447C00127	Trial results awaiting further analysis and interpretation. Anticipated posting date is June 2008. Comparison.
D1441C00149	Trial results awaiting further analysis and interpretation. Anticipated posting date is January 2009.
D1443L00003	RAPID – An Open-Label, Randomised, Multicentre Phase IIIb Study to Evaluate the Efficacy and Tolerability of Quetiapine IR (Immediate Release), over 14 Days, in Acute Schizophrenia / Schizoaffective Disorder (Rapid versus Conventional Titration)
D1448C00007	A Multicenter, Double-blind, Randomized, Parallel-group, Placebocontrolled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Extended-release (SEROQUEL XR™) in Combination with an Antidepressant in the Treatment of Patients with Major Depressive Disorder with Inadequate Response to an Antidepressant Treatment (Onyx Study)

D1449L00003

Fast Titration of Quetiapine versus Currently Approved Titration: A Randomized, Multicentre, Parallel Group, Open Trial in Schizophrenia and Schizoaffective Disorder.

[Legal notice](#) [Privacy policy](#)

© AstraZeneca 2005